186 related articles for article (PubMed ID: 10338885)
1. Establishment registration and listing for manufacturers of human cellular and tissue-based products--FDA. Proposed rule; reopening of comment period.
Fed Regist; 1998 Dec; 63(237):68212-3. PubMed ID: 10338885
[TBL] [Abstract][Full Text] [Related]
2. Establishment registration and listing for manufacturers of human cellular and tissue-based products--FDA. Proposed rule.
Fed Regist; 1998 May; 63(93):26744-55. PubMed ID: 10179343
[TBL] [Abstract][Full Text] [Related]
3. Human cells, tissues, and cellular and tissue-based products; establishment registration and listing. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2001 Jan; 66(13):5447-69. PubMed ID: 11503777
[TBL] [Abstract][Full Text] [Related]
4. Medical devices; establishment registration and device listing for manufacturers and distributors of devices; correction--FDA. Proposed rule; correction.
Fed Regist; 1998 Nov; 63(228):65566. PubMed ID: 10338876
[TBL] [Abstract][Full Text] [Related]
5. Medical devices; establishment registration and device listing for manufacturers and distributors of devices--FDA. Direct final rule.
Fed Regist; 1998 Sep; 63(188):51825-7. PubMed ID: 10185812
[TBL] [Abstract][Full Text] [Related]
6. Medical devices; establishment registration and device listing for manufacturers and distributors of devices; companion to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 Sep; 63(188):51874-5. PubMed ID: 10185813
[TBL] [Abstract][Full Text] [Related]
7. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license; correction--FDA. Proposed rule; correction.
Fed Regist; 1998 Sep; 63(170):46718. PubMed ID: 10182705
[TBL] [Abstract][Full Text] [Related]
8. Medical devices; preemption of state product liability claims--FDA. Withdrawal of proposed rule.
Fed Regist; 1998 Jul; 63(142):39789-90. PubMed ID: 10181516
[TBL] [Abstract][Full Text] [Related]
9. Medical devices; establishment registration and device listing for manufacturers and distributors of devices; correction--FDA. Direct final rule; correction.
Fed Regist; 1998 Nov; 63(228):65554-5. PubMed ID: 10338874
[TBL] [Abstract][Full Text] [Related]
10. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring; extension of comment period--FDA. Proposed rule; extension of comment period.
Fed Regist; 1998 Aug; 63(148):41219-20. PubMed ID: 10181522
[TBL] [Abstract][Full Text] [Related]
11. Human cells, tissues, and cellular and tissue-based products; establishment registration and listing. Interim final rule; opportunity for public comment.
Food and Drug Administration, HHS
Fed Regist; 2004 Jan; 69(17):3823-6. PubMed ID: 14968801
[TBL] [Abstract][Full Text] [Related]
12. Use of materials derived from cattle in human food and cosmetics; reopening of the comment period. Interim final rule; reopening of the comment period.
Food and Drug Administration, HHS
Fed Regist; 2013 Mar; 78(42):14012-3. PubMed ID: 23476996
[TBL] [Abstract][Full Text] [Related]
13. Medical devices; review and revision of compliance policy guides and regulatory requirements for refurbishers, rebuilders, reconditioners, servicers and "as is" remarketers of medical devices; request for comments and information; extension of comment period--FDA. Advance notice of proposed rulemaking; extension of comment period.
Fed Regist; 1998 Mar; 63(57):14390-1. PubMed ID: 10177751
[TBL] [Abstract][Full Text] [Related]
14. Letter to manufacturers of blood establishment computer software products--FDA. Notice.
Fed Regist; 1994 Aug; 59(168):44991-2. PubMed ID: 10136917
[TBL] [Abstract][Full Text] [Related]
15. Control of communicable diseases; restrictions on African rodents, prairie dogs, and certain other animals. Interim final rule; supplement and partial reopening of comment period.
Food and Drug Administration, HHS
Fed Regist; 2007 Feb; 72(34):7825-6. PubMed ID: 17319058
[TBL] [Abstract][Full Text] [Related]
16. Revisions to the general safety test requirements for biological products--FDA. Direct final rule: confirmation in part and withdrawal in part.
Fed Regist; 1998 Aug; 63(150):41718. PubMed ID: 10181723
[TBL] [Abstract][Full Text] [Related]
17. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
[TBL] [Abstract][Full Text] [Related]
18. Medical devices; reconditioners, rebuilders of medical devices; revocation of compliance policy guide; request for comments--FDA. Notice.
Fed Regist; 1998 Dec; 63(233):67076-8. PubMed ID: 10338883
[TBL] [Abstract][Full Text] [Related]
19. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
[TBL] [Abstract][Full Text] [Related]
20. Medical devices; preemption of state product liability claims--FDA. Proposed rule.
Fed Regist; 1997 Dec; 62(239):65384-8. PubMed ID: 10176832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
